Prostate cancer in Saskatchewan Canada, before and during the PSA era

Cancer Causes and Control

Volumn 11, Issue 1, 2000, Pages 79-88

  Skarsgard, David ^a   Tonita, Jon ^b  

^a Saskatoon Cancer Center   (Canada)

^b SASKATCHEWAN CANCER AGENCY   (Canada)

Author keywords

Incidence; Mortality; Prostate specific antigen; Screening; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANADA; HUMAN; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RETROSPECTIVE STUDY; SURVIVAL;

AGED; AGED, 80 AND OVER; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SASKATCHEWAN; SURVIVAL ANALYSIS;

EID: 0033627746     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008965617078     Document Type: Article

References (30)

1. National Cancer Institute of Canada (1998) Toronto (Canada): Canadian Cancer Statistics.
2. Chen VW, Wu XC, Andrews PA, eds (1998) Cancer in North America, 1990-94. Sacramento, CA: North American Association of Central Cancer Registries, 1: 239.
3. Percy C, Van Holten V, Muir C, eds (1990) International Classification of Diseases for Oncology, 2nd edn. Geneva: World Health Organization.
4. Waterhouse J, Muir C, Correa P, Powell J, eds (1976) Cancer Incidence in Five Continents. Lyon: International Agency for Research on Cancer, 3: 57.
5. Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds (1987) Cancer Incidence in Five Continents. Lyon: International Agency for Research on Cancer, 5: 128.
6. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, eds (1992) Cancer Incidence in Five Continents. Lyon: International Agency for Research on Cancer, 6: 132.
7. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds (1997) Cancer Incidence in Five Continents. Lyon: International Agency for Research on Cancer, 7: 1186.
8. World Health Organization (1997) International Classification of Diseases; 1975 Revision. Geneva: World Health Organization, 1.
9. Hakulinen T (1982) Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 38: 933-942.
10. Hakulinen T, Tenkanen L (1987) Regression analysis of relative survival rates. Appl Stat 36: 309-317.
11. Dean AG, Dean JA, Coulombier D, et al. (1995) Epi Info, Version 6: A Word-Processing, Database and Statistics Program for Public Health on IBM-compatible Microcomputers. Atlanta: Centers for Disease Control and Prevention.
12. Voutilainen ET, Dickman PW, Hakulinen T (1998). SURV2: Relative Survival Analysis Program Version 2.01 β. Finnish Cancer Registry, Helsinki, and Cancer Epidemiology Unit, Stockholm, 1998.
13. Francis B, Green M, Payne C, eds (1993) The GLIM System: Release 4. Oxford: Oxford University Press.
14. Shibata A, Ma J, Whittemore AS (1998) Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90: 1230-1231.
15. Brawley OW (1997) Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 80: 1857-1863.
16. Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW (1998) Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995. Eur J Cancer 34: 705-709.
17. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. (1995) Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 275: 1155-1156.
18. Levi F, La Vecchia C, Randimbison L, Erler G, Te VC, Franceschi S (1998) Incidence, mortality and survival from prostate cancer in Vaud and Neuchatel, Switzerland, 1974-1994. Ann Oncol 9: 31-35.
19. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW (1990) Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 82: 1624-1628.
20. Devesa SS, Silverman DT, Young JL Jr, et al. (1987) Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 79: 701-770.
21. Ellison LF, Stokes J, Gibbons L, Lindsay J, Levy I, Morrison H (1998) Monograph series on aging-related diseases: X. Prostate cancer. Chronic Dis Can 19: 1-18.
22. Brasso K, Friis S, Kruger Kjaer S, Jorgensen T, Iversen P (1998) Prostate cancer in Denmark: a 50-year population-based study. Urology 51: 590-594.
23. Stephenson RA, Stanford JL (1997) Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 15: 331-335.
24. Zaridze DG, Boyle P, Smans M (1984) International trends in prostatic cancer. Int J Cancer 15: 223-230.
25. Etzioni R, Cha R, Feuer EJ, Davidov O (1998) Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 148: 775-785.
26. Menegoz F, Colonna M, Exbrayat C, Mousseau M, Orfeuvre H, Schaerer R (1995) A recent increase in the incidence of prostatic carcinoma in a French population: role of ultrasonography and prostatic specific antigen. Eur J Cancer 31A: 55-58.
27. Meyer F, Moore L, Bairati I, Fradet Y (1998) Quebec prostate cancer mortality dropped in 1996. Cancer Prev Control 2: 163-166.
28. Threlfall TJ, English DR, Rouse IL (1998) Prostate cancer incidence in Western Australia: trends in incidence and mortality from 1985 to 1996. Med J Aust 169: 21-24.
29. Smith DP, Armstrong BK (1998) Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 169: 17-20
30. Hall RR (1994) Radical prostatectomy and prostate cancer screening: the need for national audit and research. Ann Royal Coll Surg Engl 76: 367-372.